Jeff Sharman

13PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursNuclear medicinePharmaceutical delivery technologiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 21, 2025
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.

Jeff P Sharman, Bin Liu, Denise Y Wang

|Sep 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Franck Morschhauser, Gilles Salles, Laurie H Sehn

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.

Tara Graff, Ian Flinn, Jeff P Sharman

|Dec 03, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak

|Sep 26, 2024
Pirtobrutinib combinations in CLL.

Jeff P Sharman

Pageof 3

Frequent Collaborators

4 joint publications

Paolo Ghia

2 joint publications

Wojciech Jurczak

2 joint publications

John M Pagel

2 joint publications

Ian W Flinn